Who is sponsoring NCT05426382?

NCT05426382 is sponsored by Sidekick Health.

What drugs are being tested in NCT05426382?

Interventions in NCT05426382: A digital care solution for patients with NAFLD.

What condition does NCT05426382 study?

NCT05426382 studies Non Alcoholic Fatty Liver Disease.

Is NCT05426382 still recruiting?

NCT05426382 is currently completed. Last updated 26 April 2023.

Last reviewed 2023-04-26 · How we verify

NCT05426382

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease

Completed NA Last updated 26 April 2023

What this trial tests

NA trial testing A digital care solution for patients with NAFLD in Non Alcoholic Fatty Liver Disease in 38 participants. Completed in 24 April 2023.

Timeline

20 June 2022

Primary endpoint
24 April 2023

24 April 2023

Quick facts

Lead sponsor	Sidekick Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	20 June 2022
Primary completion	24 April 2023
Estimated completion	24 April 2023
Sites	2 locations across Iceland

Drugs / interventions tested

A digital care solution for patients with NAFLD

Conditions studied

Non Alcoholic Fatty Liver Disease — all drugs for Non Alcoholic Fatty Liver Disease →

Sponsor

Sidekick Health

Who can join

Adults 18 to 79, any sex, with Non Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sidekick Health has developed a digital behavioral change program (SK-241) specifically designed for people with metabolic derangements and non-alcoholic fatty liver disease (NAFLD). The SK-241 is delivered through a mobile application and aims at improving lifestyle and health outcomes by focusing on improving diet, increasing activity levels and reducing stress. In this study, the feasibility of the newly developed digital behavioral change program (SK-241) will be evaluated in a minimum of 30 individuals with a NAFLD diagnosis. The primary aim is to explore the acceptability of the SK-241 program by its users, in addition to exploring changes in clinical outcomes and medication adherence after a 12-week intervention with 6 months follow up.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study.
Björnsdottir S, Ulfsdottir H, Gudmundsson EF, Sveinsdottir K, et al · · 2024 · cited 10× · PMID 38152892 · DOI 10.2196/52576
Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study.
Björnsdottir S, Ulfsdottir H, Gudmundsson EF, Dobies B, et al · · 2025 · cited 1× · PMID 40939135 · DOI 10.2196/72074

Verify or expand the search:

Other recruiting trials for Non Alcoholic Fatty Liver Disease

Currently open trials in the same condition.

NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting

Other Sidekick Health trials

Trials by the same sponsor.

NCT06989450 — Digital Patient Support Program for Self-efficacy and Medication Adherence in Women on Adjuvant Endocrine Treatment for · NA · recruiting
NCT06112184 — Digital Health Program With Participants Using an Autoinjector · NA · completed
NCT05801965 — A Digital Therapeutic Solution for Cancer Patients · NA · completed
NCT05713565 — A Digital Care Solution for Coronary Artery Disease Patients · NA · completed
NCT05459454 — A Digital Solution for Breast Cancer Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05426382 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidekick Health
Last refreshed: 26 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05426382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing